DrugPatentWatch Database Preview

Deferasirox - Generic Drug Details

What are the generic sources for deferasirox and what is the scope of deferasirox freedom to operate?
Deferasirox is the generic ingredient in four branded drugs marketed by Novartis Pharms Corp, Actavis Elizabeth, and Novartis, and is included in four NDAs. There are two patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Deferasirox has seventy-six patent family members in forty-eight countries.

There are twenty drug master file entries for deferasirox. One supplier is listed for this compound.

Summary for deferasirox

International Patents:	76
US Patents:	2
Tradenames:	4
Applicants:	3
NDAs:	4
Drug Master File Entries:	20
Suppliers / Packagers:	1
Bulk Api Vendors:	83
Clinical Trials:	85
Patent Applications:	730
Formulation / Manufacturing:	see details
Drug Prices:	see low prices
DailyMed Link:	deferasirox at DailyMed

Pharmacology for deferasirox

Drug Class	Iron Chelator
Mechanism of Action	Iron Chelating Activity Cytochrome P450 3A4 Inducers Cytochrome P450 2C8 Inhibitors Cytochrome P450 1A2 Inhibitors

Synonyms for deferasirox

1044764-54-6
1133425-75-8
201530-41-8
4-((3E,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl)benzoic acid
4-((3Z,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl)benzoic acid
4-(3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid
4-[(3E,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid
4-[(3Z,5E)-3,5-Bis(6-Oxo-2,4-cyclohexadien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid, AldrichCPR
4-[(3Z,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid
4-[3,5-bis(2-hydroxyphenyl)
4-[3,5-Bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid
4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid
4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid
4-[3,5-bis(6-oxidanylidenecyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid
4-[3,5-bis(6-oxo-1-cyclohexa-2,4-dienylidene)-1,2,4-triazolidin-1-yl]benzoic acid
4-{5-[(1E)-6-OXOCYCLOHEXA-2,4-DIEN-1-YLIDENE]-3-[(1Z)-6-OXOCYCLOHEXA-2,4-DIEN-1-YLIDENE]-1,2,4-TRIAZOLIDIN-1-YL}BENZOIC ACID
530D418
A814288
AB0020007
AB0073018
AB01565800_02
AB1008603
AC-8972
AC1NUU0E
AC1O1JMP
ACM1133425758
AKOS015855839
AKOS015902587
AKOS025312553
AN-5418
BC677677
BCP9000594
BDBM50088376
Benzoic acid, 4-(3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)-
Benzoic acid, 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-
BOFQWVMAQOTZIW-UHFFFAOYSA-N
C21H15N3O4
CAS-201530-41-8
CGP-72670
CHEBI:49005
CHEMBL550348
CS-0901
CTK8F0690
D03669
D0Q5UQ
DB01609
Deferasirox (Exjade)
Deferasirox (JAN/USAN/INN)
Deferasirox [USAN:INN:JAN]
Deferasirox [USAN:INN]
Deferasirox-d4
Deferasirox, ICL670
Deferasiroxum
Deferasiroxum [INN-Latin]
DR002074
DSSTox_CID_28522
DSSTox_GSID_48596
DSSTox_RID_82794
DTXSID1048596
Exjade
Exjade (TN)
F0001-2380
FT-0601564
HE297142
HE323479
HMS3655A04
HSDB 7844
HY-17359
I14-1968
ICL 670
ICL 670A
ICL-670
ICL-670A
ICL670
ICL670A
J-013060
Jadenu
Jadenu (TN)
Jadenu Sprinkle
KB-49640
KE-0220
KS-00000G02
LS-186571
LS-187785
MFCD09751362
MFCD09951804
MLS003915634
MLS006010080
MolPort-006-392-553
MolPort-028-744-623
NCGC00181754-01
NCGC00263572-01
PubChem20503
s1712
SCHEMBL1071867
SCHEMBL61756
SCHEMBL62042
SMR002544689
SR-01000931971
SR-01000931971-2
Tox21_112926
Tox21_112926_1
UNII-V8G4MOF2V9
V0697
V8G4MOF2V9
W-5422
ZINC100022643
ZINC100504305
ZINC100504309
ZINC1481815
ZINC14880008

US Patents and Regulatory Information for deferasirox

+ Get email alerts for changes to this table

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-002	Mar 30, 2015		RX	Yes	No	➤ Sign Up	➤ Sign Up				➤ Sign Up
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-001	Mar 30, 2015		RX	Yes	No	➤ Sign Up	➤ Sign Up	Y	Y		➤ Sign Up
Actavis Elizabeth	DEFERASIROX	deferasirox	TABLET, FOR SUSPENSION;ORAL	203560-002	Jan 26, 2016	AB	RX	No	No	➤ Sign Up	➤ Sign Up				➤ Sign Up
Actavis Elizabeth	DEFERASIROX	deferasirox	TABLET, FOR SUSPENSION;ORAL	203560-001	Jan 26, 2016	AB	RX	No	No	➤ Sign Up	➤ Sign Up				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

Expired US Patents for deferasirox

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-001	Mar 30, 2015	➤ Sign Up	➤ Sign Up
Novartis	EXJADE	deferasirox	TABLET, FOR SUSPENSION;ORAL	021882-002	Nov 2, 2005	➤ Sign Up	➤ Sign Up
Novartis	EXJADE	deferasirox	TABLET, FOR SUSPENSION;ORAL	021882-001	Nov 2, 2005	➤ Sign Up	➤ Sign Up
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-002	Mar 30, 2015	➤ Sign Up	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Non-Orange Book US Patents for deferasirox

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
6,596,750	Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators	➤ Sign Up
6,723,742	Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Patents for deferasirox

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration
South Korea	20050098029	➤ Sign Up
Malaysia	129541	➤ Sign Up
Norway	317180	➤ Sign Up
Taiwan	533205	➤ Sign Up
Country	Document Number	Estimated Expiration

Supplementary Protection Certificates for deferasirox

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C 035/2006	Ireland	➤ Sign Up	SPC 035/2006: 20070528, EXPIRES: 20210827
C0049	France	➤ Sign Up	PRODUCT NAME: DEFERASIROX OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/06/356/001 DU 20060828; REGISTRATION NO/DATE AT EEC: EU/1/06/356/001 DU 20060828
0914118/01	Switzerland	➤ Sign Up	PRODUCT NAME: DEFERASIROX; REGISTRATION NUMBER/DATE: SWISSMEDIC 57466 03.11.2005
2007001,C0914118	Lithuania	➤ Sign Up	PRODUCT NAME: DEFERASIROXUM; REGISTRATION NO/DATE: EU/1/06/356/001 2006-08-28, EU/1/06/356/002 2006-08-28, EU/1/06/356/003 2006-08-28, EU/1/06/356/004 2006-08-28, EU/1/06/356/005 2006-08-28, EU/1/06/356/00 20060828
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description